WebNational Center for Biotechnology Information WebApr 11, 2024 · 암젠이 개발하고 있는 소세포폐암(SCLC)과 전립선암 치료제인 ‘탈라타맙’(tarlatamab)이 국내에서 개발 완성 단계에 접어들었다.식품의약품안전처는 …
First DLL3-targeted therapy shows promise in SCLC
WebJun 22, 2024 · AMG 757, or tarlatamab, demonstrated safety and efficacy among patients with small cell lung cancer, according to updated phase 1 data presented at the virtual … WebFeb 7, 2024 · Prior therapy with tarlatamab or any of the standard of care chemotherapy included as part of this trial. Prior therapy with any selective inhibitor of the DLL3 pathway. Participant received more than one prior systemic therapy regimen for SCLC. holiday inn and suites tampa fl moffitt
About Tarlatamab Tarlatamab Clinical Trials
WebJan 1, 2024 · Mechanism of tarlatamab-mediated tumor suppression in SCLC. Tarlatamab, also known as AMG 757, is a BiTE. By binding to DLL3 on tumor cells and CD3 on T cells, tarlatamab enables the recruitment ... WebApr 14, 2024 · Beyond AACR23: Immunotherapy that targets DLL3 in SCLC. In SCLC, Amgen is building on a deep legacy in a class of immunotherapies known as T-cell engagers to advance a first-in-class half-life extended (HLE) bispecific T-cell engager (BiTE ®) molecule, tarlatamab, that targets the delta-like ligand 3 protein, also known as DLL3. WebAug 8, 2024 · The registrational Phase II study on the drug as a third-line treatment has started enrolling patients, with additional trials to be launched soon, including the Phase Ib DeLLphi-303 study, which will test tarlatamab with the standard of care in first-line SCLC and the Phase Ib study in de novo or treatment-emergent neuroendocrine prostate cancer. hugh convention